Clinical trial NCT04405011: NUC in Preventing HBV Reactivation in HCV/HBV Co-infected Patients Receiving DAA for CHC
Official title: Role of Nucleoside Analogue in Preventing Clinical Reactivation of HBV in HCV/HBV Co-infected Patients Receiving DAA Therapy for Chronic Hepatitis C
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: HBV/HCV Co-infection
Keywords: HCV,HBV
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2020-05-28
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: HBV reactivation is common in HCV/HBV coinfected patients receiving DAA therapy for chronic hepatitis C. How to prevent HBV reactivation remains unclear. In this trial, we aim to investigate whether prophylactic nucleos(t)ide analogue (NUC) at the start of DAA could prevent HBV reactivation or not. And whether prolonged NUC prophylaxis (24 weeks) would be better than 12-week prophylaxis. This will be a three-arm, open-label, randomized, active controlled, study. Totally, 60 HBV/HCV co-infected treatment-naïve or treatment-experienced patients without decompensated liver cirrhosis will be included in this study. Group 1 patients (n=20) will receive 12-week ETV from the start of DAA therapy. Group 2 patients (n=20) will receive 24-week ETV from the start of DAA till 12 weeks after end of DAA. Group 3 patients (n=20) will not receive ETV during the period of DAA and will serve as controls. The rate of HBV reactivation and clinical reactivation will be compared among 3 groups of patients. Expected outcomes: The rate of HBV reactivation and clinical reactivation will be lower in the ETV prophylaxis group, and will be the lowest in the group receiving 24-week ETV prophylaxis.

Detailed description: We will determine the incidence of virologic and clinical reactivation of HBV during DAA treatment for CHC, in two prophylactic groups versus control group. We will also examine whether extending the duration of prophylactic NUC would be more beneficial than the 3-month prophylaxis regimen.

Patients with the following criteria will be enrolled: age ≥20 years; anti-HCV positive and HCV RNA \>1000 IU/ml; any HCV genotype; all received 12 weeks of DAA treatment; treatment naïve or experienced of pegylated interferon/ribavirin; concurrent HBV infection which is defined by positive HBsAg for at least 6 months. Patients with the following criteria will be excluded: history of treatment regimen that included any kind of direct antiviral agents; presence of other etiology of chronic hepatitis including HIV, autoimmune hepatitis, NASH, etc; uncontrolled diabetes mellitus (Hba1c \>8.5); current evidence or suspicion of malignancy; severe cardiovascular or other severe comorbid diseases; autoimmune disorders; presence of liver cirrhosis clinically or pathologically; any one of following hematology or biochemical or clinical abnormalities: AST/ALT \>10x ULN, Albumin \<3.5g/dL, Bilirubin \>2.5mg/dL, eGFR \<30 ml/min/1.73m2, prothrombin time prolongation \>4 sec or INR \>1.7, platelet count \<100 x 103 uL, and history or presence of ascites or hepatic encephalopathy; child-bearing age women without the willing to contraceptive control; and pregnant women or lactating women.

Briefly, 60 HCV/HBV coinfected patients will be enrolled and randomized to receive 12-week DAA regimen for reimbursed for the the treatment of patients with CHC in Taiwan.

Entecavir (0.5mg; ETV) 1 # daily will be used in the prophylactic group. Group 1 patients (n=20) will receive 12-week ETV from the start of DAA therapy. Group 2 patients (n=20) will receive 24-week ETV from the start of DAA till 12 weeks after end of DAA. Group 3 patients (n=20) will not receive ETV during the period of DAA and serve as controls. The rate of HBV reactivation and clinical reactivation will be compared among 3 groups of patients.

The primary endpoint will be the incidence of virologic and clinical reactivation of HBV during DAA treatment for CHC. Secondary objectives include the rate of HBV virologic and clinical reactivation between 12-week versus 24-week entecavir (ETV) prophylaxis during and after DAA treatment; the profiles of serum HBV DNA/qHBsAg during and after DAA treatment; and sustained virological response at post-DAA treatment 12 weeks (SVR12).

The data will be expressed as percentages for category variables and as mean +- standard deviation for continuous variables. Category variables will be evaluated by Chi-square test or Fisher exact test. Student's t test or Mann-Whitney U test will be applied for comparison of the continuous variables. Multivariate analysis will be used to identify factors that are associated with HBV reactivation. A p value less than 0.05 is considered to be significant.

Eligibility criteria: Inclusion criteria

1. Age ≥20 years;
2. Anti-HCV positive and HCV RNA \>1000 IU/ml;
3. Any HCV genotype; all received 12 weeks of DAA treatment.
4. Treatment naïve or experienced of pegylated interferon/ribavirin;
5. Concurrent HBV infection which is defined by positive HBsAg for at least 6 months.

Exclusion criteria

1. History of treatment regimen that included any kind of direct antiviral agents;
2. Presence of other etiology of chronic hepatitis including HIV, autoimmune hepatitis, NASH, etc;
3. Uncontrolled diabetes mellitus (Hba1c \>8.5);
4. Current evidence or suspicion of malignancy;
5. Severe cardiovascular or other severe comorbid diseases;
6. Autoimmune disorders;
7. Presence of liver cirrhosis clinically or pathologically;
8. Any one of following hematology or biochemical or clinical abnormalities:

   AST/ALT \>10x ULN, Albumin \<3.5g/dL, Bilirubin \>2.5mg/dL, eGFR \<30 ml/min/1.73m2, prothrombin time prolongation \>4 sec or INR \>1.7, platelet count \<100 x 103 uL, and history or presence of ascites or hepatic encephalopathy.
9. Child-bearing age women without the willing to contraceptive control; pregnant women or lactating women.

Primary outcomes:
measure: HBV virologic and clinical reactivation rates
timeFrame: 72 weeks
Secondary outcomes:
measure: HBV reactivation rate: 12-week prophylaxis versus 24-week prophylaxis
timeFrame: 72 weeks
measure: Profiles of serum HBV DNA/qHBsAg during and after DAA treatment.
timeFrame: 72 weeks
measure: Sustained virological response at post-DAA treatment 12 weeks (SVR12)
timeFrame: 72 weeks
Other outcomes:
Locations:
city: Taipei City
country: Taiwan
facility: National Taiwan University Hospital
city: Taipei
country: Taiwan
facility: TC Chen
Study officials:
affiliation: Department of Internal Medicine, NTUH
name: Chun-Jen Liu, MDPHD
role: PRINCIPAL_INVESTIGATOR
References: